Micro-Cap Pharmaceutical Stocks
Comprehensive directory and speculative guide to the high-risk, high-reward world of Micro-Cap Pharmaceutical Stocks in 2026.
Navigating the landscape of Micro-Cap Pharmaceutical Stocks requires a disciplined focus on clinical trial milestones, FDA PDUFA dates, and cash runway metrics. As of early 2026, the sector is defined by extreme volatility, where a single Phase 3 readout can drive triple-digit gains for companies in the biotech section. To assist with due diligence, investors frequently use our compare micro-cap pharma tool to benchmark burn rates against sector averages. While many firms in this segment are pre-revenue, those focusing on small-cap pharma tiers often provide a glimpse into the next generation of blockbuster therapies. This directory tracks the primary innovators currently defining the all sectors healthcare framework.
Key Takeaways
Performance is almost exclusively driven by clinical milestones, with Phase 3 liver and oncology readouts creating massive 2026 momentum.
With an average 80% burn rate, identifying firms with 12+ months of liquidity is essential to avoid dilutive secondary offerings.
Micro-caps with orphan designations benefit from 7-year exclusivity, significantly boosting the valuation of early-stage pipelines.
Successful Phase 2 data often makes these companies primary acquisition targets for Big Pharma, frequently resulting in significant premiums.
Top Micro-Cap Pharmaceutical Stocks by Market Cap (2026)
The following leaders represent the most active micro-cap pharmaceutical entities by valuation and 2026 price performance.
| Rank | Ticker | Company | Industry | Market Cap | YTD % | Phase | Cash Runway |
|---|---|---|---|---|---|---|---|
| 1 | ETON | Eton Pharmaceuticals | Specialty Pharma | $451M | +25% | Commercial | 18+ Mos |
| 2 | CTMX | CytomX Therapeutics | Oncology | $376M | +137% | Phase 2 | 12 Mos |
| 3 | GALT | Galectin Therapeutics | Liver Disease | $263M | +211% | Phase 3 | 9 Mos |
| 4 | SVRA | Savara Inc. | Orphan/Rare | $185M | +15% | Phase 3 | 14 Mos |
| 5 | CANF | Can-Fite BioPharma | Biotechnology | $7.2M | +8% | Phase 2 | 6 Mos |
| 6 | NBY | NovaBay Pharma | Therapeutics | $6.9M | -5% | Commercial | 7 Mos |
| 7 | WINT | Windtree Therapeutics | Cardiology | $14M | +63% | Phase 2 | 5 Mos |
| 8 | OGEN | Oragenics, Inc. | Infectious Disease | $1.2M | -12% | Phase 1 | 4 Mos |
Micro-Cap Pharmaceutical Stocks — Complete Company List
List of Publicly Traded Micro-Cap Pharmaceutical Companies Listed on Major U.S. Exchanges
- List of Pharmaceutical Companies
- Large-Cap Pharmaceuticals
- Mid-Cap Pharmaceuticals
- Small-Cap Pharmaceuticals
- Biotech
- Micro-Cap Pharmaceutical Industry Comparison Widget
Pharmaceuticals: Micro-Cap Stocks
- Corium International, Inc. (CORI) (Transdermal and transmucosal delivery systems; Alzheimer’s disease; partners include Procter & Gamble)
- Cumberland Pharmaceuticals Inc. (CPIX) (Acetaminophen poisoning; pain and fever; prescription laxative; hyponatremia; H. pylori and duodenal ulcer disease; kidney failure)
- PLx Pharma Inc. (PLXP) (Develops safer/more effective aspirin products using its PLxGuard delivery system)
- scPharmaceuticals Inc. (SCPH) (IPO November 17, 2017; pharmaceutical company: products designed to be delivered via subcutaneous (under the skin)
- VTV Therapeutics Inc. (VTVT) (IPO in July 2015: Clinical stage pharmaceutical company: cancer, central nervous system disorders, diabetes and metabolic disorders, inflammation)
ADHD
- Neos Therapeutics, Inc. (NEOS) (IPO in July 2015: Attention deficit hyperactivity disorder)
Animal Health
- Aratana Therapeutics, Inc. (PETX) (Pet therapeutics company)
Anti-Biotics
- Tetraphase Pharmaceuticals, Inc. (TTPH) (Antibiotics platform based on the tetracycline core)
Cancer
- ESSA Pharma Inc. (EPIX) (Canada: small molecule drugs for the treatment of prostate cancer)
- Oasmia Pharmaceutical AB (OASM) (IPO in October 2015, Sweden: Human and animal oncology)
Central Nervous System
- Zogenix, Inc. (ZGNX) (Therapies for CNS and pain-related conditions)
Drug Delivery
- Intellipharmaceutics International Inc. (IPCI) (Canada: controlled-release and targeted-release oral solid dosage drugs)
- Oramed Pharmaceuticals Inc. (ORMP) (Israel: platform for oral delivery of drugs)
- SteadyMed Ltd (STDY) (IPO in March 2015: Specialty pharmaceutical company; pump delivery products for injectable drugs)
Eyes
- Alimera Sciences, Inc. (ALIM) (Ophthalmic pharmaceuticals)
Fungal Infections
- SCYNEXIS, Inc. (SCYX) (Serious and life-threatening invasive fungal infections)
Infectious Diseases
- Melinta Therapeutics, Inc. (MLNT) (Antibacterial products used in the treatment of infectious diseases)
Pain
- AcelRx Pharmaceuticals, Inc. (ACRX) (Therapies for the treatment of acute pain)
- Aralez Pharmaceuticals Inc. (ARLZ) (Specialty pharmaceutical company: cardiovascular, pain management)
- Avenue Therapeutics, Inc. (ATXI) (IPO June 27, 2017; specialty pharmaceutical company: postoperative pain management)
- BioDelivery Sciences International, Inc. (BDSI) (Pain management and addiction medicine)
- Egalet Corporation (EGLT) (Medicines for patients with moderate to severe pain)
- KemPharm Inc. (KMPH) (IPO in April 2015: Specialty pharmaceutical company: prodrugs that are designed to improve one or more attributes of currently approved drugs; pipeline includes pain, ADHD and CNS indications)
- Recro Pharma, Inc. (REPH) (Non-opioid therapeutics for the treatment of acute post-operative pain)
Respiratory
- Adamis Pharmaceuticals Corporation (ADMP) (Respiratory disease, allergy)
- Savara Inc. (SVRA) (Specialty pharmaceutical company: rare respiratory diseases)
Testosterone
- Lipocine Inc. (LPCN) (Testosterone replacement)
Women’s Health
- Agile Therapeutics, Inc. (AGRX) (Contraceptive products)
- Juniper Pharmaceuticals, Inc. (JNP) (Specialty pharmaceutical company: therapeutics that address unmet medical needs)
Anti-bodies
- Immune Pharmaceuticals Inc. (IMNP) (Antibody therapeutics: inflammatory diseases and cancer)
Cancer
- Midatech Pharma plc (MTP) (Oncology treatment and supportive care products)
- Moleculin Biotech, Inc. (MBRX) (IPO June 2, 2016: clinical stage pharmaceutical company, anticancer drug candidates)
Consumer Health
- Biostar Pharmaceuticals, Inc. (BSPM) (China: manufacturer of pharmaceutical and health supplement products; over-the-counter medicine for chronic hepatitis B)
- ProPhase Labs, Inc. (PRPH) (Over-the-counter cold remedy, consumer health products, natural base health products, supplements, cosmeceuticals)
Drug Delivery
- Zosano Pharma Corporation (ZSAN) (IPO in January 2015: Drug delivery: osteoporosis, hypoglycemia and migraine)
Ear, Nose and Throat
- Novus Therapeutics, Inc. (NVUS) (Specialty pharmaceutical company: ear, nose, and throat disorders)
Eyes
- Eyegate Pharmaceuticals, Inc. (EYEG) (Specialty pharmaceutical and drug delivery company: therapies and drug delivery technologies)
Gastrointestinal
- Evoke Pharma, Inc. (EVOK) (Drugs to treat gastrointestinal disorders and diseases)
- Ritter Pharmaceuticals Inc. (RTTR) (IPO in June 2015: Specialty pharmaceutical company: gastrointestinal diseases)
Pain
- Pernix Therapeutics Holdings, Inc. (PTX) (Specialty, primary care and generic medicines; neurology and pain management)
Respiratory
- Aradigm Corporation (ARDM) (Severe respiratory disease)
Skin
- Sonoma Pharmaceuticals, Inc. (SNOA) (Specialty pharmaceuticals: wound management, dermatology, women’s health and animal health)
Women’s Health
- BioPharmX Corporation (BPMX) (Specialty pharmaceuticals: women’s health and dermatology)
Risks & Considerations
Binary Clinical Outcome Risk
Most micro-cap pharma stocks rely on a single drug candidate. A failed Phase 2 or 3 trial typically results in an immediate 80-90% loss of capital.
Chronic Share Dilution
Constant cash burn for R&D requires frequent capital raises. "At-the-market" offerings often dilute existing shareholders significantly before a drug ever reaches commercialization.
Limited Market Liquidity
Low daily trading volumes mean large buy or sell orders can cause massive slippage, making it difficult to exit positions during a downward trend.
FDA Regulatory Uncertainty
Even successful clinical trials do not guarantee approval. Manufacturing issues or "Complete Response Letters" (CRLs) from the FDA can delay revenue by years.